Cargando…

Management of Antiviral Resistance in Chronic Hepatitis B

The primary goal of therapy for chronic hepatitis B (CHB) is to prevent liver disease progression. Hepatitis B surface antigen (HBsAg) seroclearance or seroconversion is regarded as an optimal endpoint to discontinue treatment. However, HBsAg seroclearance occurs very rarely with nucleos(t)ide analo...

Descripción completa

Detalles Bibliográficos
Autor principal:	Lim, Young-Suk
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Editorial Office of Gut and Liver 2017
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5347642/ https://www.ncbi.nlm.nih.gov/pubmed/28183162 http://dx.doi.org/10.5009/gnl15562

Ejemplares similares

Current Antiviral Therapy for Chronic Hepatitis B
por: Lim, Young-Suk, et al.
Publicado: (2004)

Antiviral therapy for chronic hepatitis B in China
por: Zheng, Xin, et al.
Publicado: (2014)

Advances in new antivirals for chronic hepatitis B
por: Tang, Yanhua, et al.
Publicado: (2022)

Current Trend in Antiviral Therapy for Chronic Hepatitis B
por: Chien, Rong-Nan, et al.
Publicado: (2022)

Benefits and Risks of Antiviral Treatment during Pregnancy in Patients with Chronic Hepatitis B
por: Lee, Yoon Seok, et al.
Publicado: (2021)

Adverse effects of oral antiviral therapy in chronic hepatitis B
por: Kayaaslan, Bircan, et al.
Publicado: (2017)

Antiviral Treatment of Chronic Hepatitis B Virus (HBV) Infections(†)
por: De Clercq, Erik, et al.
Publicado: (2010)

The treatment of chronic hepatitis B: Focus on adefovir-like antivirals
por: Tillmann, Hans Ludger
Publicado: (2008)

Novel Antivirals in Clinical Development for Chronic Hepatitis B Infection
por: Mak, Lung-Yi, et al.
Publicado: (2021)

Time for an active antiviral therapy for hepatitis B: An update on the management of hepatitis B virus infection
por: Chae, Hee Bok, et al.
Publicado: (2007)

Primary Hepatic Small-Cell Carcinoma Developed during Antiviral Treatment for Chronic Hepatitis B
por: Kim, Suk Bae
Publicado: (2015)

Options for the management of antiviral resistance during hepatitis B therapy: reflections on battles over a decade
por: Yim, Hyung Joon, et al.
Publicado: (2013)

Antiviral efficacies of currently available rescue therapies for multidrug-resistant chronic hepatitis B
por: Park, Mi Sung, et al.
Publicado: (2013)

Strategies for treating and managing chronic hepatitis C in children in the direct-acting antiviral era
por: Hong, Suk-Jin, et al.
Publicado: (2020)

Antiviral Therapy in Lamivudine-Resistant Chronic Hepatitis B Patients: A Systematic Review and Network Meta-Analysis
por: Wang, Hui-Lian, et al.
Publicado: (2016)

Impact of prior lamivudine use on the antiviral efficacy and development of resistance to entecavir in chronic hepatitis B patients
por: Hwang, Joo An, et al.
Publicado: (2015)

Hepatitis C Virus and Antiviral Drug Resistance
por: Kim, Seungtaek, et al.
Publicado: (2016)

Management of hepatitis C viral infection in chronic kidney disease patients on hemodialysis in the era of direct-acting antivirals
por: Ko, Soon Young, et al.
Publicado: (2018)

How to compare antivirals in the treatment of chronic hepatitis B?
por: Ozaras, Resat, et al.
Publicado: (2009)

Discontinuation of antiviral therapy in chronic hepatitis B patients
por: Medas, Renato, et al.
Publicado: (2021)

Challenges in the discontinuation of chronic hepatitis B antiviral agents
por: Kaewdech, Apichat, et al.
Publicado: (2021)

The assessment of hepatocellular carcinoma risk in patients with chronic hepatitis B under antiviral therapy
por: Varbobitis, Ioannis, et al.
Publicado: (2016)

Hepatitis B Core Antibody Level: A Surrogate Marker for Host Antiviral Immunity in Chronic Hepatitis B Virus Infections
por: Shi, Yang, et al.
Publicado: (2023)

Entecavir versus tenofovir in patients with chronic hepatitis B: Enemies or partners in the prevention of hepatocellular carcinoma
por: Lee, Sung Won, et al.
Publicado: (2021)

Molecular diagnostics in the management of chronic hepatitis C: key considerations in the era of new antiviral therapies
por: Cobb, Bryan, et al.
Publicado: (2014)

The Discovery and Development of a Potent Antiviral Drug, Entecavir, for the Treatment of Chronic Hepatitis B
por: Tang, Hong, et al.
Publicado: (2013)

Prevention and Management of Chronic Hepatitis B
por: Bhat, Mamatha, et al.
Publicado: (2014)

Evidence for Benefits of Early Treatment Initiation for Chronic Hepatitis B
por: Lim, Young-Suk, et al.
Publicado: (2023)

Innate Antiviral Immune Responses to Hepatitis B Virus
por: Ait-goughoulte, Malika, et al.
Publicado: (2010)

Antiviral Therapy in Chronic Hepatitis B With Mild Acute Exacerbation
por: Lin, Su, et al.
Publicado: (2017)

Current Antiviral Therapy of Chronic Hepatitis B: Efficacy and Safety
por: Lam, Yuk-Fai, et al.
Publicado: (2011)

Antiviral Treatment among Pregnant Women with Chronic Hepatitis B
por: Fan, Lin, et al.
Publicado: (2014)

Antiviral treatment for chronic hepatitis B: Safety, effectiveness, and prognosis
por: Wu, Ya-Li, et al.
Publicado: (2019)

Unmet need in chronic hepatitis B management
por: Liang, Lilian Yan, et al.
Publicado: (2019)

Novel biomarkers for the management of chronic hepatitis B
por: Inoue, Takako, et al.
Publicado: (2020)

Direct Acting Antivirals for the Treatment of Chronic Viral Hepatitis
por: Karayiannis, Peter
Publicado: (2012)

Recent Advances in Antiviral Therapy for Chronic Hepatitis C
por: Tamori, Akihiro, et al.
Publicado: (2016)

Liver-related effects of chronic hepatitis C antiviral treatment
por: Laursen, Tea L, et al.
Publicado: (2020)

New era for management of chronic hepatitis C virus using direct antiviral agents: A review
por: Elbaz, Tamer, et al.
Publicado: (2015)

Naturally occurring hepatitis B virus reverse transcriptase mutations related to potential antiviral drug resistance and liver disease progression
por: Choi, Yu-Min, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_cven3ks6bb2otvrk9tu89hqm6m